Mestag Therapeutics has announced the first patient dosed with MST-0312 in the Phase I STARLYS trial, evaluating the safety and anti-tumor activity of the targeted lymphotoxin-beta (LTBR) agonist bispecific antibody in advanced solid tumors, including in combination with pembrolizumab.
The STARLYS trial is a first-in-human, adaptive, multi-part, multi-arm, open-label study designed to assess safety, tolerability, pharmacodynamics, pharmacokinetics, and anti-tumor activity of MST-0312, with initial focus on tumors in barrier organs such as lung, gut, bladder, breast, and skin.
Under the leadership of Principal Investigator Emilio Emmanuel Delgado Sánchez, the trial is being conducted at the START Madrid-CIOCC (Centro Integral Oncológico Clara Campal) Hospital in Madrid, Spain, marking a significant milestone in developing a new therapeutic class targeting fibroblast immunology.
Sources:
Mestag Therapeutics Announces the First Patient Dosed with
MST-0312 - Drug Targets, Indications, Patents - Patsnap Synapse
Mestag Therapeutics Selected to Present Targeted LTBR Agonist ...
Uncategorized – 1stOncology™: Cancer Intelligence Service
Mestag Therapeutics to Present Novel LTBR Agonist MST-0312 ...
Phase 1 open label trial of MST-0312 alone and in combination in ...
Mestag Therapeutics to Present Data on Targeted LTBR Agonist ...
Mestag Therapeutics Announces $40 Million Financing and ...
Mestag Therapeutics raises $40M and adds leadership ...
Mestag Therapeutics » Signaling a new era in immunotherapy
Mestag Therapeutics Announces $40 Million Financing and ...
Mestag Therapeutics: $40 Million Raised To Advance Fibroblast ...
Mestag Therapeutics: $40 Million Raised To Advance Fibroblast ...
Mestag Therapeutics Announces $40 Million Financing and Appoints